Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib

    Zaiwen Fan
    Zaiwen Fan
    Aiping Zeng
    Aiping Zeng
    Rong Yin
    Rong Yin
    Yangming Ou
    Yangming Ou
    Zhihui Shi
    Zhihui Shi
    Jie Yin
    Jie Yin

    Lung cancer (Amsterdam, Netherlands), 2019.

    Cited by: 0|Bibtex|Views4|Links
    WOS
    Keywords:
    Acquired resistanceConcurrent genomic landscapeNext-generation sequencingNon-small cell lung cancerOsimertinibMore(1+)

    Abstract:

    Known EGFR-dependent resistant mutations and activation of alternative pathways were identified in 44 % of all the patients with great heterogeneity. Gain-of-function mutations of CTNNB1 were highly enriched in our cohort. Some other putative resistance mechanisms to osimertinib, such as the recurrent EGFR V834 L mutation, were also ident...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments